Achaogen (NASDAQ:AKAO) major shareholder Robert W. Duggan acquired 47,361 shares of the company’s stock in a transaction that occurred on Wednesday, April 4th. The shares were acquired at an average cost of $12.44 per share, for a total transaction of $589,170.84. Following the purchase, the insider now directly owns 6,411,108 shares of the company’s stock, valued at $79,754,183.52. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Achaogen stock opened at $12.15 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.83 and a current ratio of 4.83. Achaogen has a 52-week low of $9.83 and a 52-week high of $27.49.
Achaogen (NASDAQ:AKAO) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.21). The firm had revenue of $1.87 million during the quarter, compared to analysts’ expectations of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. equities research analysts predict that Achaogen will post -3.47 EPS for the current fiscal year.
Several equities research analysts recently commented on AKAO shares. Stifel Nicolaus dropped their price objective on shares of Achaogen from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, February 28th. Needham & Company LLC reissued a “buy” rating and set a $20.00 price objective (down previously from $29.00) on shares of Achaogen in a research note on Wednesday, February 28th. Guggenheim reissued a “buy” rating and set a $14.00 price objective on shares of Achaogen in a research note on Wednesday, January 10th. HC Wainwright boosted their price objective on shares of Achaogen from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, Mizuho reissued a “buy” rating and set a $28.00 price objective on shares of Achaogen in a research note on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $23.56.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3337503/insider-buying-achaogen-akao-major-shareholder-buys-589170-84-in-stock.html.
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.